
OrthoPediatrics (KIDS) Stock Forecast & Price Target
OrthoPediatrics (KIDS) Analyst Ratings
Bulls say
OrthoPediatrics Corp has demonstrated a positive financial performance, highlighted by a 50 basis point year-over-year increase in gross margin and a substantial 280 basis point improvement in adjusted EBITDA margin. Sales in the Trauma & Deformity segment rose by 17.3% to $44.1 million, exceeding expectations, while the overall revenue growth outlook remains strong, with management projecting a revenue increase of over 12% in the coming years. Furthermore, the company is poised for continued margin improvement and enhanced cash flow, driven by new product introductions and increased distributor productivity.
Bears say
OrthoPediatrics Corp is facing a negative outlook due to slower-than-expected revenue growth, with KIDS revenue increasing only 12% in 3Q25 compared to 16% in 2Q25, indicating a decline in sales momentum. Additionally, the company lowered its FY25 revenue guidance to $233.5M-$234.5M, reflecting concerns about disappointing sales from recently acquired products and insufficient new product launches contributing to margin improvement. Furthermore, the deployment of product sets has decreased, falling to $4.1M in 3Q25, a 23% decline from the prior year's 3Q, which raises concerns regarding future cash flow sustainability and overall financial performance.
This aggregate rating is based on analysts' research of OrthoPediatrics and is not a guaranteed prediction by Public.com or investment advice.
OrthoPediatrics (KIDS) Analyst Forecast & Price Prediction
Start investing in OrthoPediatrics (KIDS)
Order type
Buy in
Order amount
Est. shares
0 shares